Scientists test how a new drug behaves in damaged livers
NCT ID NCT06052566
Summary
This study aimed to understand how a drug for fatty liver disease (NASH) is processed by the body in people with moderate to severe liver damage. Researchers compared 22 participants—some with liver impairment and some healthy—after they received a single dose. The main goal was to measure drug levels in the blood and check for safety, not to treat the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Advanced Pharma CR, LLC ( Site 0001)
Miami, Florida, 33147, United States
-
American Research Corporation ( Site 0002)
San Antonio, Texas, 78215, United States
-
Clinical Pharmacology of Miami ( Site 0005)
Miami, Florida, 33014-3616, United States
-
Genesis Clinical Research, LLC ( Site 0006)
Tampa, Florida, 33603, United States
Conditions
Explore the condition pages connected to this study.